A Rockville drug company working on treatments for central nervous system diseases has shifted its sales force from face-to-face interactions to virtual field calls and meetings in response to the COVID-19 pandemic.
Supernus Pharmaceuticals Inc. said Monday that its entire sales and marketing organization is using digital and online startegies already used by its commercial organization.
Additionally, supplies of the company’s seizure drug Trokendi XR and anticonvulsant drug Oxtellar XR have not been impacted by the pandemic.
Suprenus is still preparing for the commercial launch of a new drug to treat attention deficit hyperactivity disorder. The company in November submitted a new drug application to the Food and Drug Administration. Supernus said Monday that the company has had no interaction with the FDA that would lead it to believe that application is delayed because of the COVID-19 pandemic, though that could be a possibility in the future.